Gerresheimer to Expand High Value Solutions
Attractive growth projects, including new biologics orders in both High Value Solutions and Contract Manufacturing are fuelling Gerresheimer’s transformation into a solution provider and underlining its position as a strategic partner of choice for the global pharma and biotech industries. The company’s expertise and strong track record are enabling it to accelerate sustainable, profitable growth by consistently increasing the revenue share of biologics solutions and injectables. In particular “ready-to-fill” solutions in syringes and vials are driving growth in High Value Solutions while Medical Devices such as auto injection devices and pens are boosting growth in the area of Contract Manufacturing.
"Gerresheimer has achieved important milestones on its transition towards becoming an innovation leader, solution provider and system integrator. We have continuously improved our competitiveness with a focus on customer centricity, innovation and operational excellence," said Dietmar Siemssen, CEO of Gerresheimer. “Our formula g strategy process is paying off and generating sustainable growth across all our divisions. With new orders for High Value Solutions and Medical Devices, we have further reinforced our leading positions in attractive markets. We will continue to shift the portfolio from volume to value and expand our margins.”
Gerresheimer is the market leader for vials with a market share of more than 30%. There is a disproportionate growth potential in high value vials and cartridges. On the back of the successful market conversion in syringes, shifting from bulk towards ready-to-fill of 95% percent over the last decade, the new industry standard EZ-fill smart supports the repetition of this success story for vials and cartridges.
